BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11135214)

  • 1. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
    Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
    Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
    Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
    Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
    J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating benign and malignant pulmonary lesions with FDG-PET.
    Yang SN; Liang JA; Lin FJ; Kwan AS; Kao CH; Shen YY
    Anticancer Res; 2001; 21(6A):4153-7. PubMed ID: 11911310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
    Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
    J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
    Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
    Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-time point
    Parghane RV; Basu S
    Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
    Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
    Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
    Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
    Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.
    Sperti C; Pasquali C; Chierichetti F; Liessi G; Ferlin G; Pedrazzoli S
    Ann Surg; 2001 Nov; 234(5):675-80. PubMed ID: 11685032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
    Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
    Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.